Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

The basket pairs Regeneron’s cash flow with Moderna’s Aug. 5 FDA decision and Viking’s obesity pipeline, analysts said.

Summary by The Motley Fool
The next six months may be decisive for the biotech.

3 Articles

The Motley FoolThe Motley Fool
Lean Left

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

The next six months may be decisive for the biotech.

·Alexandria, United States
Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)

Gilead Sciences HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Read why GILD stock is a buy.

·Ra'anana, Israel
Read Full Article
24/7 Wall St.24/7 Wall St.
Center

3 Biotech Stocks With Massive Upside to Buy Before August Starts

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.

·Lakewood, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

24/7 Wall St. broke the news in Lakewood, United States on Wednesday, July 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

HIV icon

HIV

Gilead Sciences icon

Gilead Sciences

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal